Recombinant Protein-Based COVID-19 Vaccines Workshop (9:00 a.m. additional doses that may be administered at the discretion of the healthcare provider, taking into consideration the individual’s clinical circumstances.a fourth dose administered at least 1 month following the most recent dose. Today, the FDA authorized the following uses of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent for individuals 6 months through 4 years of age with certain types of immunocompromise who have previously received three 0.2 mL doses (Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent): requested the voluntary withdrawal of the EUA for this vaccine. On Thursday, the FDA revoked the emergency use authorization (EUA) of the Janssen COVID-19 Vaccine. This discussion will include consideration of the vaccine composition for fall to winter, 2023-2024. The committee will discuss and make recommendations on the selection of strain(s) to be included in the periodic updated COVID-19 vaccines for the 2023-2024 vaccination campaign. Vaccines and Related Biological Products Advisory Committee The FDA has advised manufacturers seeking to update their COVID-19 vaccines that they should develop vaccines with a monovalent XBB.1.5 composition. The FDA posted information regarding the formula for COVID-19 vaccines for the 2023-2024 fall and winter seasons. Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |